TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
+10.56%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.98B
AUM Growth
+$171M
(+9.4%)
Cap. Flow
+$118M
Cap. Flow
% of AUM
5.98%
Top 10 Holdings %
Top 10 Hldgs %
35.03%
Holding
220
New
18
Increased
34
Reduced
52
Closed
20
Top Buys
| 1 |
Vera Therapeutics
VERA
|
$28.3M |
| 2 |
Merus
MRUS
|
$26.3M |
| 3 |
Mettler-Toledo International
MTD
|
$22.9M |
| 4 |
Boeing
BA
|
$20.9M |
| 5 |
Spyre Therapeutics
SYRE
|
$17.2M |
Top Sells
| 1 |
Dynavax Technologies
DVAX
|
$37.7M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$29M |
| 3 |
SLRN
ACELYRIN
SLRN
|
$24.3M |
| 4 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$10.1M |
| 5 |
CRISPR Therapeutics
CRSP
|
$9.07M |
Sector Composition
| 1 | Healthcare | 94.16% |
| 2 | Technology | 1.37% |
| 3 | Industrials | 1.32% |
| 4 | Communication Services | 1.26% |
| 5 | Consumer Discretionary | 0.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
101
DELISTED
SpringWorks Therapeutics
SWTX
| $3.49M | 0.18% |
74,265
| – | – |
|
102
Beam Therapeutics
BEAM
$1.88B
| $3.49M | 0.18% |
205,000
+155,000
| +310% | +$2.64M |
|
|
ATYR
103
aTyr Pharma
ATYR
$536M
| $3.4M | 0.17% |
671,134
| – | – |
|
104
Cytokinetics
CYTK
$5.95B
| $3.3M | 0.17% |
100,000
| – | – |
|
105
Kezar Life Sciences
KZR
$28M
| $3.3M | 0.17% |
720,000
| – | – |
|
106
Iovance Biotherapeutics
IOVA
$796M
| $3.1M | 0.16% |
1,800,000
| – | – |
|
107
Theravance Biopharma
TBPH
$708M
| $2.92M | 0.15% |
264,308
+1,412
| +0.5% | +$15.6K |
|
108
Alexandria Real Estate Equities
ARE
$14.2B
| $2.91M | 0.15% |
40,000
| – | – |
|
109
Seer Inc
SEER
$113M
| $2.88M | 0.15% |
1,344,423
+50,000
| +4% | +$107K |
|
|
MTSR
110
Metsera, Inc. Common Stock
MTSR
$3.81B
| $2.85M | 0.14% |
+100,000
| New | +$2.85M |
|
111
Pyxis Oncology
PYXS
$99.8M
| $2.75M | 0.14% |
2,500,000
+1,400,000
| +127% | +$1.54M |
|
112
Precision BioSciences
DTIL
$59.3M
| $2.75M | 0.14% |
653,649
-19,683
| -3% | -$82.7K |
|
113
Mineralys Therapeutics
MLYS
$2.2B
| $2.71M | 0.14% |
200,000
| – | – |
|
114
CG Oncology
CGON
$2.36B
| $2.28M | 0.12% |
+87,500
| New | +$2.28M |
|
115
Fate Therapeutics
FATE
$112M
| $2.09M | 0.11% |
1,867,773
| – | – |
|
116
Rocket Pharmaceuticals
RCKT
$349M
| $2.08M | 0.11% |
850,000
| – | – |
|
117
Taysha Gene Therapies
TSHA
$889M
| $2.08M | 0.11% |
+900,000
| New | +$2.08M |
|
118
Biohaven
BHVN
$1.7B
| $1.98M | 0.1% |
140,000
| – | – |
|
119
CareDx
CDNA
$697M
| $1.95M | 0.1% |
100,000
| – | – |
|
120
Erasca
ERAS
$420M
| $1.91M | 0.1% |
1,502,915
+312,903
| +26% | +$397K |
|
121
Syndax Pharmaceuticals
SNDX
$1.39B
| $1.87M | 0.09% |
200,000
| – | – |
|
122
JPMorgan Chase
JPM
$835B
| $1.83M | 0.09% |
6,312
-2,542
| -29% | -$737K |
|
123
Sutro Biopharma
STRO
$86.5M
| $1.83M | 0.09% |
2,561,586
+2,361,586
| +1,181% | +$1.69M |
|
124
Zentalis Pharmaceuticals
ZNTL
$128M
| $1.8M | 0.09% |
1,550,000
+50,000
| +3% | +$58K |
|
125
Walt Disney
DIS
$214B
| $1.8M | 0.09% |
14,493
-4,133
| -22% | -$513K |
|